Ausgabe 3/2004
Inhalt (16 Artikel)
Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study
Danila Coradini, Cinzia Pellizzaro, Gabriella Abolafio, Marco Bosco, Ignazio Scarlata, Silvia Cantoni, Luca Stucchi, Sonia Zorzet, Claudia Turrin, Gianni Sava, Alberto Perbellini, Maria Grazia Daidone
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice
Heleen A. Bardelmeijer, Mariët Ouwehand, Jos H. Beijnen, Jan H. M. Schellens, Olaf van Tellingen
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent
Gary P. Wilkinson, James P. Taylor, Steve Shnyder, Patricia Cooper, Phil W. Howard, David E. Thurston, Terence C. Jenkins, Paul M. Loadman
In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug
Esther F. A. Brandon, Rolf W. Sparidans, Irma Meijerman, Ignasio Manzanares, Jos H. Beijnen, Jan H. M. Schellens
A novel mammalian cell-based approach for the discovery of anticancer drugs with reduced cytotoxicity on non-dividing cells
Valeria Gonzalez-Nicolini, Cornelia Fux, Martin Fussenegger
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
K. Gelmon, H. Hirte, B. Fisher, W. Walsh, M. Ptaszynski, M. Hamilton, N. Onetto, E. Eisenhauer
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma
Thomas E. Hutson, Ram Ganapathi, Paul Elson, Tarek Mekhail, Thomas Olencki, G. Thomas Budd, Ronald M. Bukowski
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients
Alex Sparreboom, Sharon Marsh, Ron H. J. Mathijssen, Jaap Verweij, Howard L. McLeod
Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
Valerie Israel, Scott T. Tagawa, Terry Snyder, Susan Jeffers, Derek Raghavan
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer
Eardie A. Curry III, Daryl J. Murry, Christy Yoder, Karen Fife, Victoria Armstrong, Harikrishna Nakshatri, Michael O’Connell, Christopher J. Sweeney
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer
Paulo M. Hoff, Everardo D. Saad, Richard Pazdur, Robert Wolff, Yvonne Lassere, Karla R. Bogaard, James L. Abbruzzese
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
Susan Burdette-Radoux, Richard G. Tozer, Reinhard C. Lohmann, Ian Quirt, D. Scott Ernst, Wendy Walsh, Nancy Wainman, A. Dimitrios Colevas, Elizabeth A. Eisenhauer
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium
Hedy L. Kindler, Anjali Avadhani, Kurombi Wade-Oliver, Theodore Karrison, Sridhar Mani, Everett E. Vokes
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors
M.J.A. de Jonge, J.P. Droz, L. Paz-Ares, A.T. van Oosterom, R. de Wit, P. Chollet, B. Baron, D. Lacombe, K. Mettinger, P. Fumoleau
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study
Robert P. Whitehead, Jacqueline K. Benedetti, James L. Abbruzzese, Bach Ardalan, J. Wendall Goodwin, Stanley P. Balcerzak, Wolfram E. Samlowski, Heinz-Josef Lenz, John S. Macdonald
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
Russell J. Schilder, John A. Blessing, Michael L. Pearl, Peter G. Rose